Subgroup analyses
As displayed in Figure 1C , all 10 patients in the combined radiotherapy
group were in a more stable condition than that in the non-combined
radiotherapy group (DCR=100.00%) (P < 0.05) ,and patients
with better performance status exhibited a trend of higher DCR than
those with poorer performance status (88.23% vs.74.00% vs.18.18%) (P
< 0.05). Patients in the first-line treatment group
(ORR=48.0%) revealed relatively higher ORR and longer PFS than those
treated with the PD-1 inhibitor-based therapy as second- or late-line
therapy (ORR: 48.00% vs. 13.20%, P = 0.001, Figure 1D ; PFS:
7.67
months vs. 5.57 months, P = 0.129, Figure 2A). As shown in Figure 2B,
PFS was 1.44 months (95%CI:0.00-4.34) for monotherapy versus 7.34
months (95%CI:4.50-10.18) for combination therapy (P=0.053), which was
not statistically significant, but it was worth observing that 17 out of
the 19 (89.47%) patients who achieved a partial response were on
combination therapy. Significant difference was observed in the PFS of
different combination groups (PD-1 antibody alone vs. PD-1 antibody
combined with the chemotherapy vs. PD-1 antibody combined with the
bevacizumab vs. PD-1 antibody combined with the chemotherapy and the
bevacizumab groups: 1.44 vs.5.67 vs.1.67 vs.14.13, Figure 2C). Patients
with combined radiotherapy showed longer PFS than those without combined
radiotherapy (14.07 vs.4.62, P=0.027) (Figure 2D). The evaluation of
lesion for the efficacy of ICI therapy and irradiation site were the
same sites in all the patients treated with radiotherapy, and the
treatment processes are presented in Table 2.